Publication & Citation Trends
Publications
0 total
Utility of in silico prediction of target suppression for antibodies against soluble targets: static versus dynamic models
Cited by 0
Semantic Scholar
Prediction of Half-Life Extension of Peptides via Serum Albumin Binding: Current Challenges
Cited by 25
Semantic Scholar
Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes OA
Cited by 34
Semantic Scholar
Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma OA
Cited by 26
Semantic Scholar
A novel dual glucagon‐like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo‐controlled first‐in‐human and first‐in‐patient trials
Cited by 141
Semantic Scholar
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL OA
Cited by 67
Semantic Scholar
Phase 1/2 Study in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Receiving Blinatumomab Treatment
Cited by 26
Semantic Scholar
Research Topics
Acute Lymphoblastic Leukemia research
(18)
Chronic Myeloid Leukemia Treatments
(16)
Macrophage Migration Inhibitory Factor
(10)
Monoclonal and Polyclonal Antibodies Research
(8)
CAR-T cell therapy research
(7)
Affiliations
Université Claude Bernard Lyon 1
Roche (Switzerland)
Novartis (Switzerland)
Amgen (Germany)
Sanofi (Germany)